• Natural Reconstruction

     

    Improving the quality of life of breast cancer survivors.

     

    Every year, more than 2.8 million women undergo breast surgery. Based on the number of breast cancer diagnosis and statistics of tumor resections, we estimated that in 2017 approx. 956,000 women worldwide underwent reconstructive surgery after a mastectomy or a lumpectomy (i.e. total or partial breast removal, respectively) and ~226,000 breast surgery revisions have been performed. According to the International Society of Plastic Surgery (ISAPS), breast augmentation represents the world’s leading aesthetic surgical procedure, with ~1.65 million operations performed in 2016. The most commonly used technologies for breast tissue defects are silicone or saline implants. These prostheses are not lifetime devices and need to be substituted over time, leading to high costs for the healthcare stakeholders and significant pain for the patients. Moreover, silicone implants do not represent a solution for patients who are eligible for a breast-conserving surgery (lumpectomy) since they are not customizable based on the defect size.

  • EU H2020 project "REGENERA"

    With the goal of solving these problems, Tensive created the project REGENERA to develop a cell-free porous scaffold made of resorbable biomaterials with a biomimetic architecture which aims to promote blood vessels and soft tissue recruitment. It is designed to be gradually replaced by the patients’ soft tissue, allowing to restore a natural aspect and feeling of the reconstructed breast. The technology has not yet been tested in humans.

     

    REGENERA project has been funded by the European Union's Horizon 2020 research and innovation programme, under grant agreement No 812002, for a total budget of €2.69 million. The goal of the project is to complete the development of a breakthrough solution for breast reconstruction, in particular for post-lumpectomy patients, for whom there are no definitive, optimal reconstructive options available.

  • About

    Expected Advantages.

     

    Clinical validation required. The technology has not yet been tested in humans.

    AESTHETIC OUTCOME

    Natural shape

    DEFINITIVE SOLUTION

    No reoperation required

    COST-SAVING

    Single surgery

    SAFE DEVICE

    No leakage & ruptures

  • NATURAL FEELING

    Restoration of a natural sensation

    RELIABLE IMAGING

    Not masking recurrences

    EASY-to-ADOPT

    Procedure for surgeons

    QUALITY of LIFE

    For breast cancer survivors

  • News

    Milan, May 31st, 2018 - Tensive S.r.l., the biomedical company pioneering innovative implants for breast reconstruction and augmentation, has announced that it has been awarded a grant for a total budget of €2.69 million from the prestigious European Union’s Horizon 2020 research and innovation...
    Tensive's project, Regenera, has been admitted to the Regione Lombardia "Linea R&S per Aggregazioni" research grant. The project includes the preclinical validation of Tensive's innovative prosthesis, with a total budget of €1.2 M and with the support of prestigious academic and industrial partners.
  • Contact Us

    Viale Ortles 22/4, 20139, Milano (Italy)
    +39 (0) 2 5666 0153
    All Posts
    ×